Although not studied in asthma, low-dose IL-2 therapy has been found beneficial in patients with diseases including graft-versus-host disease, many of whom were receiving glucocorticoids (46), and hepatitis C virus–induced vasculitis (47). Here, IL2 is linked to graft versus host disease.